SCHEMBL3962067

SCHEMBL3962067

CC(C)(C)OC(=O)NCc1ccc2ccsc2c1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.46
KDM4A O75164 1/20 0.44
BRD9 Q9H8M2 1/20 0.43
BAZ2B Q9UIF8 1/20 0.43
BAZ2A Q9UIF9 1/20 0.43
GRM2 Q14416 1/20 0.43
DYRK1A Q13627 1/20 0.42
NAMPT P43490 2/20 0.42
GAA P10253 1/20 0.41
GLS O94925 2/20 0.41
HDAC1 Q13547 1/20 0.41
TSHR P16473 1/20 0.40
MAPT P10636 2/20 0.40
TDP1 Q9NUW8 1/20 0.40
RECQL P46063 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15485753 0.90 ROCK2 (0.45) L3MBTL1KDM4ABRD9BAZ2BBAZ2A
SCHEMBL12855291 0.80 MAPT (0.48) HDAC1TSHRMAPTNPSR1
SCHEMBL3180689 0.78 L3MBTL1 (0.61) L3MBTL1KDM4ANAMPTGAAHDAC1
SCHEMBL30627625 0.77 CA2 (0.45) NAMPTTSHRMAPTTDP1NPSR1
SCHEMBL16506623 0.77 L3MBTL1 (0.47) L3MBTL1GRM2DYRK1ANAMPTGLS
SCHEMBL4672100 0.77 NQO2 (0.52) L3MBTL1KDM4ABRD9BAZ2BBAZ2A
SCHEMBL12853154 0.77 ERCC1 (0.56) HDAC1TSHRMAPT
SCHEMBL3968727 0.77 CA12 (0.48) NAMPTGAAHDAC1CA1
SCHEMBL24052929 0.75 L3MBTL1 (0.46) L3MBTL1GRM2NAMPTGAAHDAC1
SCHEMBL30679780 0.75 DYRK1A (0.46) L3MBTL1KDM4AGRM2DYRK1ANAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1989200-B1 [4-(BENZO[B]THIOPHEN-2-YL)-PYRIMIDIN-2-YL]-AMINE DERIVATIVES AS IKK-BETA INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES LILLY CO ELI (US) 2009-07-29 EP disclosed
US-7547691-B2 [4-(Benzo[B]thiophen-2-yl) Pyrimidin-2-yl]-amine derivatives as IKK-beta inhibitors for the treatment of cancer and inflammatory diseases ELI LILLY AND COMPANY (US) 2009-06-16 US disclosed
US-20080306082-A1 [4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases ELI LILLY AND COMPANY 2008-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306082-A1 [4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases NFKBIA, IKBKB, IKBKG L3MBTL1 2789/4885KDM4A 559/4885BRD9 108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.